AC Immune S.A.

Suisse


Commandez votre montre hebdomadaire AC Immune S.A.
Quantité totale PI 264
Rang # Quantité totale PI 4 982
Note d'activité PI 3/5.0    151
Rang # Activité PI 4 457
Symbole boursier ACIU (nasdaq)
ISIN CH0329023102
Capitalisation 311M  (USD)
Industrie Biotechnology
Secteur Healthcare
Classe Nice dominante Produits chimiques destinés à l'...

Brevets

Marques

96 6
56 4
96 2
4
 
Dernier brevet 2025 - Method of safe administration of...
Premier brevet 2004 - Methods and compositions compris...
Dernière marque 2019 - AC IMMUNE
Première marque 2006 - AFFITOPE

Industrie (Classification de Nice)

Derniers inventions, produits et services

2025 Invention Method of safe administration of phosphorylated tau peptide vaccine. Methods for inducing anti-p...
Invention Alpha synuclein therapeutic vaccine. The present invention relates to immunogenic compositions th...
Invention Novel compounds. The present invention relates to novel compounds for the treatment, alleviation ...
Invention Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway...
Invention Liposomes containing phosphorylated tau peptides for inducing sustained immune responses. Method...
2024 Invention Antibody drug conjugates targeting proteinopathies, and uses thereof. The invention provides anti...
Invention Heterocyclic modulators of the nlrp3 inflammasome pathway. The present application relates to com...
Invention Assays and methods for assessing vaccine preparations. Provided herein are assays and methods of ...
Invention Tau active functional assays. The application describes methods for evaluating the capacity of an...
Invention Method of treating preclinicial alzheimer's disease. The application describes a phosphorylated t...
Invention Method of treating preclinicial alzheimer's disease. The application describes a phosphorylated ...
Invention Diagnostic compounds that bind to alpha-synuclein. The present application relates to novel compo...
Invention Novel compounds for the treatment of disease associated with alpha-synuclein aggregates. The pres...
Invention Anti-abeta therapeutic vaccines. A liposomal vaccine composition comprises a β-amyloid (Aβ)-deri...
Invention Anti-tdp-43 binding molecules and uses thereof. The present invention is in the field of transact...
Invention Anti-abeta vaccine therapy. A liposomal vaccine composition comprising a !-amyloid (Aβ)-derived p...
Invention Liposomal construct. A liposomal construct comprises a liposome, at least one adjuvant; and a pep...
2023 Invention Vaccine therapy. The present invention provides means for treating, alleviating and preventing a...
Invention Novel compounds for diagnosis. The present invention relates to novel compounds of formula (I), o...
Invention Method of purifying a compound. 1-41-4 alkyl sulfonate as a leaving group. The compound of formul...
Invention Novel compounds for the diagnosis of tdp-43 proteinopathies. The present invention relates to com...
Invention Novel compounds. The present invention relates to novel compounds for the treatment, alleviation...
Invention Pyrrolotriazine and imidazotriazine derivatives as modulators of the nlrp3 inflammasome pathway. ...
Invention Method of safe administration of phosphorylated tau peptide vaccine. Methods for inducing anti-ph...
Invention Anti-tdp-43 binding molecules. TDP-43 binding molecules specifically binding phosphorylated TDP-4...
Invention Novel compounds for the treatment, alleviation or prevention of disorders associated with tau agg...
Invention Bicyclic compounds for diagnosis and therapy. The present invention relates to novel compounds t...
Invention Humanized anti-tdp-43 binding molecules and uses thereof. The present invention is in the field ...
Invention Humanized anti-tdp-43 binding molecules and uses thereof. The present invention is in the field o...
Invention Anti-alpha-synuclein therapeutic vaccines. The present invention relates to a liposomal vaccine ...
Invention Anti-alpha-synuclein therapeutic vaccines. 123456123456345666, wherein Y is tyrosine and E is as ...
2022 Invention Dihydro-oxazol derivative compounds. The present invention relates to novel compounds for the tr...
Invention Anti-tau antibodies and methods of use. The invention provides anti-Tau antibodies and methods o...
Invention Dihydropyrrolo[3,4-c]pyrazole derivatives and their use in diagnosis. The present invention rela...
Invention Dihydropyrrolo[3,4c]-pyrazole derivatives and their use in diagnosis. The present invention rela...
Invention 4h-imidazo[1,5-b]pyrazole derivatives for diagnosis. The present invention relates to novel comp...
Invention Misfolded tdp-43 binding molecules. The present invention is in the field of transactive respons...
Invention Method of safe administration of tau phosphopeptide conjugate. Methods for inducing anti-phospho...
Invention Novel compounds for the diagnosis of tdp-43 proteinopathies. The present invention relates to co...
2021 Invention Antibody delivery. A vector comprises a polynucleotide encoding an antibody or antibody fragment...
Invention Novel compounds. The present invention relates to novel compounds that can be employed in the tr...
Invention Immunogenic compounds. An antigenic peptide comprises the structure X1-X2-X3-X4-X5-X6-X7-P-X9-X1...
2019 P/S Chemicals for use in industry and science; chemical substances, chemical materials and chemical p...
P/S Antibody reagents for scientific purposes; cell culture reagents for laboratory use; cell culture...
P/S Diagnostic biomarkers for in vitro testing for scientific use, biological assays and kits for use...
P/S Antibody reagents for scientific purposes, cell culture reagents for laboratory use, cell culture...
2006 P/S Chemical and biological preparations for use in industry, science and laboratories. chemical pre...
P/S Chemical and biological preparations for use in industry, science and laboratories. Pharmaceutic...